Jacksonville, Florida | April 10, 2026
Johnson & Johnson has presented new clinical data for its TECNIS PureSee™ intraocular lens (IOL) at the ASCRS 2026 Annual Meeting, demonstrating exceptional contrast sensitivity, extended range of vision, and high patient satisfaction. The findings, derived from two major studies across the U.S., Europe, and Asia-Pacific, highlight the performance of this next-generation Extended Depth of Focus (EDOF) lens, reinforcing its role in advancing modern cataract surgery outcomes and visual rehabilitation. The data confirm that TECNIS PureSee IOL delivers superior distance and intermediate vision with minimal visual disturbances, supporting its growing adoption in clinical ophthalmology.
Clinical Studies Confirm Superior Vision Outcomes
The presented data include results from both real-world observational studies and randomized clinical trials, involving hundreds of patients across multiple global sites. In real-world settings, TECNIS PureSee IOL demonstrated mean binocular uncorrected distance vision of 20/19, along with high levels of spectacle independence, with 96% for distance and 95% for intermediate vision. Patients reported minimal visual disturbances, with over 90% experiencing little to no glare, halos, or starbursts, indicating excellent visual quality.
Additionally, the lens showed high tolerance to postoperative refractive errors, a critical factor in ensuring consistent patient outcomes. In randomized clinical trials, the IOL delivered improved intermediate and near vision compared to standard monofocal lenses, while maintaining comparable distance vision and contrast sensitivity, confirming its clinical superiority and versatility.
Advanced EDOF Technology Enhances Patient Experience
Advertisement
The TECNIS PureSee IOL is designed using purely refractive EDOF technology, which enables a broader range of clear vision across distances while minimizing common side effects associated with multifocal lenses. This innovation allows patients to achieve functional vision for daily activities with reduced dependence on glasses, significantly improving quality of life. The lens is also integrated with the TECNIS SIMPLICITY™ Delivery System, ensuring precise implantation and ease of use for surgeons, which is critical for achieving optimal surgical outcomes.
Indicated for adult patients undergoing cataract surgery, the lens addresses both aphakia and presbyopia, offering a comprehensive solution for vision correction. The strong clinical evidence presented further strengthens surgeon confidence and supports wider clinical adoption of this advanced technology.
Regulatory and Clinical Impact in Modern Ophthalmology
As an FDA-approved medical device, the TECNIS PureSee IOL reflects adherence to strict regulatory standards, including design controls, clinical validation, and quality system requirements, ensuring safety and effectiveness. From a cGxP perspective, the development and commercialization of such devices involve compliance with Good Clinical Practice (GCP) and Quality Management Systems (QMS), which are essential for maintaining product reliability and patient safety.
The presentation of robust clinical data at a leading scientific forum such as ASCRS highlights the importance of post-market evidence and real-world data in validating device performance. This advancement aligns with the broader trend toward patient-centric, minimally invasive, and high-precision medical technologies, driving innovation in ophthalmology and improving surgical outcomes globally.
The latest clinical data presented by Johnson & Johnson demonstrate that TECNIS PureSee IOL represents a significant advancement in cataract surgery and vision correction, combining innovative optical design, strong clinical evidence, and high patient satisfaction. By delivering extended depth of focus, reduced visual disturbances, and improved functional vision, the technology sets a new benchmark in ophthalmic medical devices. As healthcare continues to evolve toward precision and patient-centered care, innovations like TECNIS PureSee IOL are expected to play a critical role in enhancing outcomes and redefining standards in modern eye care.
Source: Johnson and Johnson press release
